The Legend of I-SPY 2 - Part B episode artwork

EPISODE · Jul 21, 2025 · 25 MIN

The Legend of I-SPY 2 - Part B

from In the Interim... · host Berry

In this episode, Dr. Don Berry and Dr. Scott Berry provide an in-depth account of I-SPY 2, focusing on the trial’s use of the “time machine” methodology—a Bayesian solution allowing bridging across arms to inform ongoing analyses. The discussion details how predictive probabilities and adaptive randomization shaped pivotal decisions, including the handling of Pertuzumab’s approval and Neratinib’s subtype-specific performance. This episode also documents the technical and operational contributions of Laura Esserman, Anna Barker, Janet Woodcock, Meredith Buxton, and Ashish Sanil, clarifying the roles that enabled the platform’s success and broader impact on subsequent adaptive trials.Key HighlightsIntroduction of the “time machine” concept, enabling valid comparison between experimental and control arms even when enrollment periods differ—a pragmatic solution originally utilized in sports examples for evolving platform trials as treatments and control arms change.Ongoing trial conduct driven by a Bayesian adaptive algorithm, developed and maintained by Berry Consultants statisticians, which computes predictive probabilities to guide arm graduation, futility, and real-time adjustment of randomization probabilities.Neratinib serves as a case study in subtype-specific adaptive randomization: the platform set randomization probability to zero in subtypes without signal, while effective subtypes increased randomization and advanced to graduation.I-SPY 2’s methodologies shaped subsequent adaptive platform trials (GBM AGILE, Precision Promise, COVID-19 ACTIV networks), with regulatory acceptance reflected in FDA guidance and Janet Woodcock’s public recognition of adaptive randomization as “adequate and well controlled” for registration studies.Specific recognition: Laura Esserman (trial leadership), Anna Barker (funding and strategic input), Janet Woodcock (FDA guidance and adaptive methods support), Meredith Buxton (logistics; GCAR leadership), and Ashish Sanil (Berry Consultants; ongoing algorithm implementation).

Episode metadata supplied by the publisher feed · Published Jul 21, 2025

Embed this episode

NOW PLAYING

The Legend of I-SPY 2 - Part B

0:00 25:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of In the Interim...?

This episode is 25 minutes long.

When was this In the Interim... episode published?

This episode was published on July 21, 2025.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this In the Interim... episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!